Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

Revolution Medicines' pancreatic cancer drug daraxonrasib received FDA approval and could generate peak revenues of $11 billion. Royalty Pharma, which financed the drug, stands to earn up to $340 million in peak royalties without doing the development work. While Revolution Medicines stock has surged 200% in the past year, Royalty Pharma offers a more diversified alternative with investments in 35 approved drugs and a 1.4% dividend yield.